april 2023

The Risk of Hypothyroidism in Breast Cancer Patients Treated with Anti-oestrogens Tamoxifen and Letrozole

Anti-oestrogen tamoxifen, but not letrozole, is related to the risk of subclinical hypothyroidism and can influence the observed weight gain in breast cancer patients.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Få adgang
Hvis du allerede har en profil: Log ind

Forfatter

Djordje Marina

MD, Specialist in Internal Medicine and Endocrinology, PhD student, Department of Endocrinology and Metabolism Rigshospitalet, Copenhagen, Denmark

Forfatter

Åse Krogh Rasmussen

MD, DMSc., Department of Endocrinology and Metabolism Rigshospitalet, Copenhagen, Denmark

Forfatter

Kristian Buch-Larsen

MD, PhD, Department of Endocrinology and Metabolism Rigshospitalet, Copenhagen, Denmark & Senior resident physician, Amager Hospital, Denmark

Forfatter

Linn Gillberg

Postdoc, PhD, MSc. Department of Endocrinology and Metabolism Rigshospitalet, Copenhagen, Denmark & Department of Biomedical Sciences, Center for Healthy Aging Copenhagen, University of Copenhagen, Copenhagen, Denmark

Forfatter

Michael Andersson

MD, DMSc. Department of Oncology, Centre for Cancer and Organ Diseases, Rigshospitalet, Copenhagen, Denmark

Forfatter

Peter Schwarz

Professor, Overlæge, dr.med., Endokrinologisk Klinik, Rigshospitalet

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen

The Risk of Hypothyroidism in Breast Cancer Patients Treated with Anti-oestrogens Tamoxifen and Letrozole

Få adgang

Relateret indhold

Brænder du for at skrive?